Neurological Disorder Drugs Market
Neurological Disorders Drugs Market Size, Share & Trends Analysis Report, By Indication (Epilepsy, Parkinson’s Disease, Alzheimer’s Disease, Multiple Sclerosis, and Others), By Distribution Channel (Hospital Pharmacies, Retail Pharmacies, and Online Pharmacies), Forecast Period (2022-2028) Update Available - Forecast 2024-2030
Neurological disorders drugs market is anticipated to grow at a CAGR of 6.4% during the forecast period. According to a new United Nations (UN) report issued, up to 1 billion people, nearly 1 in 6 of the world’s population, suffer from neurological disorders, from Alzheimer's and Parkinson's disease, strokes, multiple sclerosis and epilepsy to migraine, brain injuries and neuro-infections, with some 6.8 million dying of the maladies each year. The integration of emerging technologies such as AI has fastened the process of R&D and diagnosis of a patient with neurological disorder thereby boosting the growth of the market. The rising drug development and manufacturing activities coupled with the rising R&D expenditure in the pharmaceutical industry is primarily contributing to the growth of the neurological disorder drugs market. For instance, Pfizer invested nearly $8.4 billion in 2019 to nearly $13.8 billion in 2021 in R&D. Further, the rising funding for neurological disorder drugs research is expected to offer an opportunity for market growth. However, high costs involved in R&D and manufacturing and strict regulatory norms are major restraints to the growth of the market.
Segmental Outlook
The global neurological disorder drugs market is segmented based on the indication and distribution channel. Based on the disease, the market is segmented into epilepsy, Parkinson’s disease, Alzheimer’s disease, multiple sclerosis, and others. Based on the distribution channel, the market is segmented into hospital pharmacies, retail pharmacies, and online pharmacies. Among indication segments, the epilepsy disease segment is projected to hold a dominant share in the market. The segmental growth of the market is attributed to the increased prevalence of Parkinson’s disease among people across the globe. A broad range of drugs is used for the treatment of neurological disorders. Some of which include analgesics, antihypertensive, anticholinergic, hypnotic & sedatives, and others.
Regional Outlook
The global neurological disorders drugs market is further segmented based on geography including North America (the US and Canada), Europe (UK, Italy, Spain, Germany, France, and Others), Asia-Pacific (India, China, Japan, South Korea, and Others), and the Rest of the World (the Middle East & Africa and Latin America). The market can be analyzed for a particular region or country level as per the requirement. North American region is expected to hold a considerable share in the global neurological disorders drugs market. The rising prevalence of neurological disorders and increasing FDA approvals for neurological drugs are some factors accelerating the market growth in the region.
Global Neurological Disorders Drugs Market Growth, by Region 2022-2028
Market Players Outlook
The major companies serving the global neurological disorders drugs market include AstraZeneca plc, AbbVie Inc., GlaxoSmithKline plc, Novartis International AG, and Pfizer Inc. The market players are contributing to the market growth by the adoption of various strategies including mergers and acquisitions, collaborations, funding, and new product launches, to stay competitive in the market. For instance, in October 2021, Tonix Pharmaceuticals expanded its operation to Frederick, Maryland, US. The company opened its newly acquired research and development center in Frederick which is located at 431 aviation Way, the 48,000 square-foot R&D facility.
Further, in April 2021, Optimus Pharma announced today that it has received approval for its Anti-Parkinson drug Safinamide. Safinamide is indicated as adjunctive treatment to levodopa/carbidopa in patients with Parkinson's disease (PD) experiencing "off" episodes. The burden of Parkinson's Disease (PD) is undeniably serious and increasing while various unmet needs remain, especially in the absence of disease-modifying therapies, especially in Indian Market. Optimus believes Safinamide will give an additional option to healthcare professionals in the treatment of Parkinson's and improve the quality of life of millions who are affected by Parkinson's disease. A homegrown generic version of Safinamide developed by Optimus will assist in delivering robust treatment for Parkinson's diseases in India with very high affordability and accessibility.
The Report Covers
- Market value data analysis of 2021 and forecast to 2028.
- Annualized market revenues ($ million) for each market segment.
- Country-wise analysis of major geographical regions.
- Key companies operating in the global neurological disorders drugs market. Based on the availability of data, information related to new product launches, and relevant news is also available in the report.
- Analysis of business strategies by identifying the key market segments positioned for strong growth in the future.
- Analysis of market-entry and market expansion strategies.
- Competitive strategies by identifying ‘who-stands-where’ in the market.
1. Report Summary
• Current Industry Analysis and Growth Potential Outlook
1.1. Research Methods and Tools
1.2. Market Breakdown
1.2.1. By Segments
1.2.2. By Region
2. Market Overview and Insights
2.1. Scope of the Report
2.2. Analyst Insight & Current Market Trends
2.2.1. Key Findings
2.2.2. Recommendations
2.2.3. Conclusion
3. Competitive Landscape
3.1. Key Company Analysis
3.1.1. AstraZeneca plc
3.1.1.1. Overview
3.1.1.2. Financial Analysis
3.1.1.3. SWOT Analysis
3.1.1.4. Recent Developments
3.1.2. AbbVie Inc.
3.1.2.1. Overview
3.1.2.2. Financial Analysis
3.1.2.3. SWOT Analysis
3.1.2.4. Recent Developments
3.1.3. GlaxoSmithKline plc
3.1.3.1. Overview
3.1.3.2. Financial Analysis
3.1.3.3. SWOT Analysis
3.1.3.4. Recent Developments
3.1.4. Novartis International AG
3.1.4.1. Overview
3.1.4.2. Financial Analysis
3.1.4.3. SWOT Analysis
3.1.4.4. Recent Developments
3.1.5. Pfizer Inc.
3.1.5.1. Overview
3.1.5.2. Financial Analysis
3.1.5.3. SWOT Analysis
3.1.5.4. Recent Developments
3.2. Key Strategy Analysis
4. Market Segmentation
4.1. Global Neurological Disorders Drugs Market by Indication
4.1.1. Epilepsy
4.1.2. Parkinson’s Disease
4.1.3. Alzheimer’s Disease
4.1.4. Multiple Sclerosis
4.1.5. Others
4.2. Global Neurological Disorders Drugs Market by Distribution Channel
4.2.1. Hospital Pharmacies
4.2.2. Retail Pharmacies
4.2.3. Online Pharmacies
5. Regional Analysis
5.1. North America
5.1.1. United States
5.1.2. Canada
5.2. Europe
5.2.1. UK
5.2.2. Germany
5.2.3. Italy
5.2.4. Spain
5.2.5. France
5.2.6. Rest of Europe
5.3. Asia-Pacific
5.3.1. China
5.3.2. India
5.3.3. Japan
5.3.4. South Korea
5.3.5. Rest of Asia-Pacific
5.4. Rest of the World
6. Company Profiles
6.1. Avilex Pharma
6.2. Bayer AG
6.3. Boehringer Ingelheim GmbH
6.4. F. Hoffmann-La Roche Ltd.
6.5. Merck & Co., Inc.
6.6. Neuraxpharm Holdco Iberia S.L.
6.7. Recursion Pharmaceuticals Inc
6.8. Teva Pharmaceutical Industries Ltd.
6.9. Tonix Pharmaceuticals Holding Corp.
1. GLOBAL NEUROLOGICAL DISORDERS DRUGS MARKET RESEARCH AND ANALYSIS BY INDICATION, 2021-2028 ($ MILLION)
2. GLOBAL NEUROLOGICAL DISORDERS DRUGS FOR EPILEPSY MARKET RESEARCH AND ANALYSIS BY REGION, 2021-2028 ($ MILLION)
3. GLOBAL NEUROLOGICAL DISORDERS DRUGS FOR PARKINSON’S DISEASE MARKET RESEARCH AND ANALYSIS BY REGION, 2021-2028 ($ MILLION)
4. GLOBAL NEUROLOGICAL DISORDERS DRUGS FOR ALZHEIMER’S DISEASE MARKET RESEARCH AND ANALYSIS BY REGION, 2021-2028 ($ MILLION)
5. GLOBAL NEUROLOGICAL DISORDERS DRUGS FOR MULTIPLE SCLEROSIS MARKET RESEARCH AND ANALYSIS BY REGION, 2021-2028 ($ MILLION)
6. GLOBAL NEUROLOGICAL DISORDERS DRUGS FOR OTHER INDICATIONS MARKET RESEARCH AND ANALYSIS BY DISTRIBUTION CHANNEL, 2021-2028 ($ MILLION)
7. GLOBAL NEUROLOGICAL DISORDERS DRUGS MARKET RESEARCH AND ANALYSIS BY DISTRIBUTION CHANNEL, 2021-2028 ($ MILLION)
8. GLOBAL NEUROLOGICAL DISORDERS DRUGS FROM HOSPITAL PHARMACIES MARKET RESEARCH AND ANALYSIS BY REGION, 2021-2028 ($ MILLION)
9. GLOBAL NEUROLOGICAL DISORDERS DRUGS FROM RETAIL PHARMACIES MARKET RESEARCH AND ANALYSIS BY REGION, 2021-2028 ($ MILLION)
10. GLOBAL NEUROLOGICAL DISORDERS DRUGS FROM ONLINE PHARMACIES MARKET RESEARCH AND ANALYSIS BY REGION, 2021-2028 ($ MILLION)
11. GLOBAL NEUROLOGICAL DISORDERS DRUGS MARKET RESEARCH AND ANALYSIS BY GEOGRAPHY, 2021-2028 ($ MILLION)
12. NORTH AMERICAN NEUROLOGICAL DISORDERS DRUGS MARKET RESEARCH AND ANALYSIS BY COUNTRY, 2021-2028 ($ MILLION)
13. NORTH AMERICAN NEUROLOGICAL DISORDERS DRUGS MARKET RESEARCH AND ANALYSIS BY INDICATION, 2021-2028 ($ MILLION)
14. NORTH AMERICAN NEUROLOGICAL DISORDERS DRUGS MARKET RESEARCH AND ANALYSIS BY DISTRIBUTION CHANNEL, 2021-2028 ($ MILLION)
15. EUROPEAN NEUROLOGICAL DISORDERS DRUGS MARKET RESEARCH AND ANALYSIS BY COUNTRY, 2021-2028 ($ MILLION)
16. EUROPEAN NEUROLOGICAL DISORDERS DRUGS MARKET RESEARCH AND ANALYSIS BY INDICATION, 2021-2028 ($ MILLION)
17. EUROPEAN NEUROLOGICAL DISORDERS DRUGS MARKET RESEARCH AND ANALYSIS BY DISTRIBUTION CHANNEL, 2021-2028 ($ MILLION)
18. ASIA-PACIFIC NEUROLOGICAL DISORDERS DRUGS MARKET RESEARCH AND ANALYSIS BY COUNTRY, 2021-2028 ($ MILLION)
19. ASIA-PACIFIC NEUROLOGICAL DISORDERS DRUGS MARKET RESEARCH AND ANALYSIS BY INDICATION, 2021-2028 ($ MILLION)
20. ASIA-PACIFIC NEUROLOGICAL DISORDERS DRUGS MARKET RESEARCH AND ANALYSIS BY DISTRIBUTION CHANNEL, 2021-2028 ($ MILLION)
21. REST OF THE WORLD NEUROLOGICAL DISORDERS DRUGS MARKET RESEARCH AND ANALYSIS BY COUNTRY, 2021-2028 ($ MILLION)
22. REST OF THE WORLD NEUROLOGICAL DISORDERS DRUGS MARKET RESEARCH AND ANALYSIS BY INDICATION, 2021-2028 ($ MILLION)
23. REST OF THE WORLD NEUROLOGICAL DISORDERS DRUGS MARKET RESEARCH AND ANALYSIS BY DISTRIBUTION CHANNEL, 2021-2028 ($ MILLION)
1. GLOBAL NEUROLOGICAL DISORDERS DRUGS MARKET SHARE BY INDICATION, 2021 VS 2028 (%)
2. GLOBAL NEUROLOGICAL DISORDERS DRUGS FOR EPILEPSY MARKET SHARE BY GEOGRAPHY, 2021 VS 2028 (%)
3. GLOBAL NEUROLOGICAL DISORDERS DRUGS FOR PARKINSON’S DISEASE MARKET SHARE BY GEOGRAPHY, 2021 VS 2028 (%)
4. GLOBAL NEUROLOGICAL DISORDERS DRUGS FOR ALZHEIMER’S DISEASE MARKET SHARE BY GEOGRAPHY, 2021 VS 2028 (%)
5. GLOBAL NEUROLOGICAL DISORDERS DRUGS FOR MULTIPLE SCLEROSIS MARKET SHARE BY GEOGRAPHY, 2021 VS 2028 (%)
6. GLOBAL NEUROLOGICAL DISORDERS DRUGS FOR OTHER INDICATIONS MARKET SHARE BY GEOGRAPHY, 2021 VS 2028 (%)
7. GLOBAL NEUROLOGICAL DISORDERS DRUGS MARKET SHARE BY DISTRIBUTION CHANNEL, 2021 VS 2028 (%)
8. GLOBAL NEUROLOGICAL DISORDERS DRUGS FROM HOSPITAL PHARMACIES MARKET SHARE BY GEOGRAPHY, 2021 VS 2028 (%)
9. GLOBAL NEUROLOGICAL DISORDERS DRUGS FROM RETAIL PHARMACIES MARKET SHARE BY GEOGRAPHY, 2021 VS 2028 (%)
10. GLOBAL NEUROLOGICAL DISORDERS DRUGS FROM ONLINE PHARMACIES MARKET SHARE BY GEOGRAPHY, 2021 VS 2028 (%)
11. GLOBAL NEUROLOGICAL DISORDERS DRUGS MARKET SHARE BY GEOGRAPHY, 2021 VS 2028 (%)
12. US NEUROLOGICAL DISORDERS DRUGS MARKET SIZE, 2021-2028 ($ MILLION)
13. CANADA NEUROLOGICAL DISORDERS DRUGS MARKET SIZE, 2021-2028 ($ MILLION)
14. UK NEUROLOGICAL DISORDERS DRUGS MARKET SIZE, 2021-2028 ($ MILLION)
15. FRANCE NEUROLOGICAL DISORDERS DRUGS MARKET SIZE, 2021-2028 ($ MILLION)
16. GERMANY NEUROLOGICAL DISORDERS DRUGS MARKET SIZE, 2021-2028 ($ MILLION)
17. ITALY NEUROLOGICAL DISORDERS DRUGS MARKET SIZE, 2021-2028 ($ MILLION)
18. SPAIN NEUROLOGICAL DISORDERS DRUGS MARKET SIZE, 2021-2028 ($ MILLION)
19. REST OF EUROPE NEUROLOGICAL DISORDERS DRUGS MARKET SIZE, 2021-2028 ($ MILLION)
20. INDIA NEUROLOGICAL DISORDERS DRUGS MARKET SIZE, 2021-2028 ($ MILLION)
21. CHINA NEUROLOGICAL DISORDERS DRUGS MARKET SIZE, 2021-2028 ($ MILLION)
22. JAPAN NEUROLOGICAL DISORDERS DRUGS MARKET SIZE, 2021-2028 ($ MILLION)
23. SOUTH KOREA NEUROLOGICAL DISORDERS DRUGS MARKET SIZE, 2021-2028 ($ MILLION)
24. REST OF ASIA-PACIFIC NEUROLOGICAL DISORDERS DRUGS MARKET SIZE, 2021-2028 ($ MILLION)
25. REST OF THE WORLD NEUROLOGICAL DISORDERS DRUGS MARKET SIZE, 2021-2028 ($ MILLION)
